ipilimumab - Robuta Search

https://adisinsight.springer.com/drugsafety/803278264?error=cookies_not_supported&code=8c9e2e45-f1f7-4d58-b27f-5aeb3a09ca37 Ipilimumab/nivolumab - AdisInsight A man in his 70s [age at the times of reactions onsets not clearly stated] developed allograft renal transplant rejection during treatment with ipilimumab nivolumab adisinsight https://adisinsight.springer.com/drugsafety/803832527?error=cookies_not_supported&code=2cbc418e-47bd-4280-8b8b-b46fd171dd23 Ipilimumab/nivolumab - AdisInsight In a multicenter, retrospective, international study (RET-MAP study) conducted between February 2012 and April 2022, a patient [age and sex not stated] was ipilimumab nivolumab adisinsight https://pubmed.ncbi.nlm.nih.gov/27932067/ Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer... Bristol-Myers Squibb. https://pubmed.ncbi.nlm.nih.gov/34380663/ Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or... https://adisinsight.springer.com/trials/700366825?error=cookies_not_supported&code=f48f8819-5f29-4a00-ba15-13f281536f48 Randomized Phase 2 Study of Nivolumab and Ipilimumab With or Without Cabozantinib in Patients With... This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib in treating patients with nasopharyngeal cancer that has https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-ipilimumab-after-radiotherapy-to-bones-for-men-already-had-docetaxel-for-prostate-cancer-ca184043 A trial of ipilimumab after radiotherapy for prostate cancer spread to the bones (CA184043) This trial looked at a drug called ipilimumab after radiotherapy for prostate cancer that has spread to the bones. https://adisinsight.springer.com/trials/700258733?error=cookies_not_supported&code=2b1750c4-5f58-48b0-a243-40792a71d568 Patterns of ipilimumab (IPI) usage and health care resource utilization in a retrospective analysis... This retrospective study assessed patterns of ipilimumab usage and healthcare resource utilisation in patients with malignant melanoma covered in a large US https://adisinsight.springer.com/drugsafety/803469771?error=cookies_not_supported&code=17cf7dab-d8d5-49ee-9bc8-c8420ab1f9c0 Ipilimumab/nivolumab/pembrolizumab - AdisInsight A retrospective review of 64 patients, described 6 patients [ages and sexes not stated], who developed colitis, hepatitis, diarrhoea, uveitis, Bell's paly or ipilimumab nivolumab pembrolizumab adisinsight https://www.businesswire.com/news/home/20210913005059/en/Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Demonstrates-Durable-Overall-Survival-at-Three-Years-Compared-to-Chemotherapy-in-First-Line-Unresectable-Malignant-Pleural-Mesothelioma-in-Phase-3-CheckMate--743-Trial Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years... Opdivo + Yervoy Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural.... https://adisinsight.springer.com/drugsafety/803641495?error=cookies_not_supported&code=1aebd253-c6f6-4106-9083-392d2d8ef0aa Warning of ipilimumab-related retinal detachment - AdisInsight The Australian Therapeutic Goods Administration (TGA) has published a Medicines Safety Update warning of the risk of ipilimumab [Yervoy]-related retinal retinal detachment warning ipilimumab related adisinsight https://experts.umn.edu/en/publications/remote-onset-alopecia-areata-attributed-to-ipilimumab/ Remote-onset alopecia areata attributed to ipilimumab - Experts@Minnesota alopecia areata remote onset attributed ipilimumab https://my.clevelandclinic.org/health/drugs/20759-ipilimumab-injection Ipilimumab injection ipilimumab injection https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-ipilimumab-advanced-non-small-cell-lung-cancer-ideate A trial looking at ipilimumab for advanced non small cell lung cancer (IDEATE) This trial looked at ipilimumab, carboplatin and paclitaxel for advanced non small cell lung cancer. small cell lung cancer https://adisinsight.springer.com/drugsafety/803883484?error=cookies_not_supported&code=8a550f12-7c8e-431a-9580-c09648b9333b COVID-19-vaccine/ipilimumab/nivolumab - AdisInsight A 47-year-old woman developed hypophysitis leading to hypoadrenalism and cerebral oedema during treatment with ipilimumab and nivolumab for malignant melanoma covid vaccine ipilimumab nivolumab adisinsight https://adisinsight.springer.com/drugsafety/803860501?error=cookies_not_supported&code=5c34b84a-56af-4d0e-8278-193a3f3bf498 Ipilimumab/nivolumab - AdisInsight A 54-year-old woman developed hepatic dysfunction, skin disorder and hypersensitivity pneumonitis during treatment with ipilimumab/nivolumab for Stage IV renal ipilimumab nivolumab adisinsight https://pubmed.ncbi.nlm.nih.gov/22396291/ Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis for the https://adisinsight.springer.com/drugsafety/803899453?error=cookies_not_supported&code=26b50769-42cf-4c58-9520-29bcdf3ac02e Ipilimumab/nivolumab/pembrolizumab - AdisInsight In a study of 60 patients conducted between January 2008 and January 2018, 5 patients (3 women and 2 men) aged between 29 and 66 years were described, who ipilimumab nivolumab pembrolizumab adisinsight https://scholars.duke.edu/publication/1134168 Scholars@Duke publication: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell... https://adisinsight.springer.com/drugsafety/803096292?error=cookies_not_supported&code=b5dfb902-5ffa-4daf-b1f8-fa2258838640 Ipilimumab - AdisInsight A 67-year-old woman developed severe enterocolitis during treatment with ipilimumab for recurrent metastatic melanoma.The woman, who had a history of recurrent ipilimumab adisinsight https://pubmed.ncbi.nlm.nih.gov/31427204/ Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell... Bristol-Myers Squibb and ONO Pharmaceutical. https://researchconnect.buffalo.edu/en/publications/pembrolizumab-versus-investigator-choice-chemotherapy-for-ipilimu/ Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma... pembrolizumab versus investigator choice chemotherapy https://adisinsight.springer.com/drugsafety/803929884?error=cookies_not_supported&code=50eece11-1c98-4ffb-9cd7-4b473d0fd872 Ipilimumab/Nivolumab - AdisInsight A 66-year-old otherwise healthy woman with localised renal cell carcinoma was treated with combination immunotherapy using the immune-checkpoint inhibitors ipilimumab nivolumab adisinsight https://publikationen.uni-tuebingen.de/xmlui/handle/10900/66724 Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naive Patients with Metastatic Uveal... https://jcto.weill.cornell.edu/open_clinical_trials/phase-ii-study-of-cabozantinib-in-combination-with-nivolumab-and-ipilimumab-in-rare-genitourinary-tumors Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary... The purpose of this study is to test the effectiveness of the drugs cabozantinib with nivolumab and ipilimumab in rare genitourinary (GU) cancers that have no... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-01041&r=1 Nivolumab and Ipilimumab in Treating Patients with Rare Tumors - NCI Nivolumab and Ipilimumab in Treating Patients with Rare Tumors nivolumab ipilimumab treating patients rare https://adisinsight.springer.com/drugsafety/803566656?error=cookies_not_supported&code=7aa5cb7b-eb3c-4920-9bc3-748d8120a5d1 Nivolumab/ipilimumab - AdisInsight A 56-year-old man developed bilateral ptosis, difficulties with handling of oral secretions, hoarseness, progressing weakness of the lower legs, slurred speech, nivolumab ipilimumab adisinsight https://pubmed.ncbi.nlm.nih.gov/33246931/ Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell... ClinicalTrials.gov identifier: NCT02231749. https://scholars.duke.edu/publication/1096294 Scholars@Duke publication: 3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab... https://pubmed.ncbi.nlm.nih.gov/35969830/ Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch... Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H... nivolumab plus ipilimumab adjuvant localized https://adisinsight.springer.com/drugsafety/803462766?error=cookies_not_supported&code=db889b6d-a2c9-4a1a-bd39-9401aadf9eca Ipilimumab/methylprednisolone/nivolumab - AdisInsight A 58-year-old man developed oral mucositis, intermittent diarrhoea and immune-related pancreatitis during treatment with ipilimumab and nivolumab for melanoma ipilimumab methylprednisolone nivolumab adisinsight https://academiccommons.columbia.edu/doi/10.7916/D8542MTX Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver... Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) that has... safety and efficacy https://profiles.wustl.edu/en/publications/expression-profiles-of-immune-related-genes-are-associated-with-n/fingerprints/ Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical... https://pubmed.ncbi.nlm.nih.gov/30110194/ CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients... Nivolumab and nivolumab plus ipilimumab demonstrated clinically meaningful antitumor activity, durable responses, encouraging long-term OS, and a manageable... efficacy and safety https://www.mdpi.com/2072-6694/16/10/1825 Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1... The efficacy of immune checkpoint inhibitor (ICI) therapy concerning programmed death ligand 1 (PD-L1) status is well established in patients diagnosed with... https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-nivolumab-and-ipilimumab-for-men-with-prostate-cancer-neptunes Cancer Research UK | A trial of nivolumab and ipilimumab for men with prostate cancer (NEPTUNES) This trial is for men with prostate cancer that has spread to other parts of the body (metastatic). cancer research uk https://adisinsight.springer.com/drugsafety/803925069?error=cookies_not_supported&code=d63f3b62-7c5d-4bc3-ac20-f23cdce3e93d Ipilimumab/Nivolumab - AdisInsight A man with malignant pleural mesothelioma developed fulminant immune-related myocarditis during treatment with ipilimumab and nivolumab. ipilimumab nivolumab adisinsight https://scholars.duke.edu/publication/1374030 Scholars@Duke publication: Nivolumab (N) alone or in combination with ipilimumab (I) in patients... https://adisinsight.springer.com/drugsafety/803106811?error=cookies_not_supported&code=b4600ca4-d102-4282-92dc-3f147e2d57b1 Ipilimumab - AdisInsight Two patients developed DRESS syndrome and acute granulomatous interstitial nephritis while receiving ipilimumab [routes not stated].A 78-year-old man had been ipilimumab adisinsight https://www.cancer.gov/research/participate/clinical-trials/intervention/ipilimumab?pn=1 Clinical Trials Using Ipilimumab - NCI NCI supports clinical trials that test new and more effective ways to treat cancer. Find clinical trials studying ipilimumab. clinical trials using ipilimumab nci https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ipilimumab-nivolumab Ipilimumab and nivolumab | Cancer Research UK Ipilimumab and nivolumab is a combination of immunotherapy treatments. Find out about how you have it, possible side effects and other important information. cancer research ipilimumab nivolumab uk https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT03036098&r=1 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the... Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of... https://scholarworks.indianapolis.iu.edu/items/bdd7bdb5-829c-40af-94a4-ee9da934919d Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma: Phase 1... Background: Recognising that the immune suppressive microenvironment promotes tumour growth in Hodgkin lymphoma, we hypothesised that activating immunity might... https://experts.umn.edu/en/projects/single-arm-phase-ii-study-of-ipilimumab-and-nivolumab-as/ Single Arm Phase II Study of Ipilimumab and Nivolumab as - Experts@Minnesota single arm phase ii https://pubmed.ncbi.nlm.nih.gov/39098455/ Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell... Superior survival, durable response benefits, and a manageable safety profile were maintained with NIVO+IPI versus SUN at 8 years, the longest phase III... https://adisinsight.springer.com/drugsafety/803216348?error=cookies_not_supported&code=2272c769-4278-48d1-8cb4-3bc558e1bd40 Ipilimumab - AdisInsight A 68-year-old man developed anterior hypopituitarism secondary to hypophysitis during treatment with ipilimumab.The man presented with headache, diplopia, ipilimumab adisinsight https://open.library.emory.edu/concern/publications/43d181d1-bf1c-435d-8d42-e23db4c3751a First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568):... First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden... small cell lung cancer https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-nivolumab-and-ipilimumab-for-small-cell-lung-cancer-stimuli A trial of nivolumab and ipilimumab for small cell lung cancer (STIMULI) This trial is looking at whether adding nivolumab and ipilimumab after chemoradiotherapy helps to stop small cell lung cancer coming back. small cell lung cancer https://pubmed.ncbi.nlm.nih.gov/29562145/?dopt=Abstract Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk... nivolumab plus ipilimumab versus sunitinib https://adisinsight.springer.com/drugsafety/803924959?error=cookies_not_supported&code=d5961966-7472-4cc2-b6fc-ca24e30a85fc Ipilimumab/Nivolumab/Pembrolizumab - AdisInsight Ten patients with metastatic melanoma experienced pseudoprogression following treatment with immune checkpoint inhibitors, including nivolumab, pembrolizumab ipilimumab nivolumab pembrolizumab adisinsight https://pubmed.ncbi.nlm.nih.gov/28167454/ Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV... The role of the assessment of peripheral T-cell phenotypes in predicting overall survival (OS) after ipilimumab treatment is unclear. Here, we analysed... https://adisinsight.springer.com/trials/700310975?error=cookies_not_supported&code=1a03f781-6902-433a-bb2c-41efa71e4435 A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid... In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended https://adisinsight.springer.com/trials/700304478?error=cookies_not_supported&code=928d8ec6-eb67-4e1f-a2c5-913ec8411247 NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT... This is a Phase II, multicenter, single-arm trial designed to evaluate the efficacy and safety of nivolumab (NIVO), ipilimumab (IPI) and temozolomide (TMZ) nivolumab plus ipilimumab temozolomide https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1187840/full Frontiers | Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on... The development of immune checkpoint inhibitors has revolutionized the landscape of treatment of advanced melanoma in recent years. Based on the efficacy res... https://pubmed.ncbi.nlm.nih.gov/27057436/ Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus... Clinical activity was observed in metastatic melanoma (MM) patients treated with ipilimumab (IPI) combined with fotemustine (FTM) in the phase II NIBIT-M1... clinical outcome https://adisinsight.springer.com/drugsafety/803878746?error=cookies_not_supported&code=86ef4471-8191-4821-b8f3-3a77bcf1f5c3 Ipilimumab/Nivolumab - AdisInsight A 79-year-old man developed drug induced diaphragmatic myopathy during treatment with nivolumab and ipilimumab for metastatic renal cell carcinoma (RCC) ipilimumab nivolumab adisinsight https://scholars.duke.edu/grant/191738 Scholars@Duke grant: A phase 1 / 2 randomized, blinded, placebo controlled study of Ipilimumab in... https://publikationen.uni-tuebingen.de/xmlui/handle/10900/76880 Vemurafenib and ipilimumab: A promising combination? Results of a case series vemurafenib ipilimumab promising combination results https://pubmed.ncbi.nlm.nih.gov/29658845/ Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor... lung cancer